Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 14;7(1):e2039. doi: 10.1038/cddis.2015.405

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Macmillan Publishers Limited

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Mcl-1 and USP9x expression was increased in highly malignant glioblastoma. Mcl-1 and USP9x protein expressions were examined in human astrocytoma (WHO grade III) and glioblastoma (WHO grade IV) tissue samples by immunohistochemical staining. (a) Representative tissue samples stained with Mcl-1 or USP9x antibodies are shown in two magnifications. (b) Staining intensity and quantity were analyzed, and the combined immunoreactive score (IRS) was calculated for Mcl-1 (right panel) and USP9x (left panel). Median IRS±S.D. is shown above the respective group and staining. **P<0.01, ***P<0.001. Mcl-1 and USP9x expressions were significantly higher in glioblastoma than in astrocytoma